Cara Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 6, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 6, 2024
TVRD$1.410.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · Accumulated · · · | |||||||||||||||||
| · · · · · · · Additional · · · · · Other · · Total | |||||||||||||||||
| · · Common Stock · · Paid-In · · Accumulated · · Comprehensive · · Stockholders’ | |||||||||||||||||
| · Shares · Amount · Capital · Deficit · Income (Loss) · Equity | |||||||||||||||||
| Balance at December 31, 2020 | | 49,872,213 | | $50 | | $641,195 | | $(392,317) | | $73 | | $249,001 | |||||
| Sale of common stock under license agreement with Vifor International ($15.23 per share) | | 3,282,391 | | | 3 | | | 44,966 | | | — | | | — | | | 44,969 |
| Stock-based compensation expense | | — | | | — | | | 17,850 | | | — | | | — | | | 17,850 |
| Shares issued upon exercise of stock options | | 136,787 | | | — | | | 1,639 | | | — | | | — | | | 1,639 |
| Shares issued upon vesting of restricted stock units | | 189,421 | | | — | | | 2,935 | | | — | | | — | | | 2,935 |
| Net loss | — | | — | | — | | (88,441) | | — | | (88,441) | ||||||
| Other comprehensive loss | — | | — | | — | | — | | (431) | | (431) | ||||||
| Balance at December 31, 2021 | | 53,480,812 | | $53 | | $708,585 | | $(480,758) | | $(358) | | $227,522 | |||||
| Stock-based compensation expense | | — | | — | | 14,345 | | — | | — | | 14,345 | |||||
| Shares issued upon exercise of stock options | | 48,307 | | — | | 311 | | — | | — | | 311 | |||||
| Shares issued upon vesting of restricted stock units | | 268,222 | | — | | 3,389 | | — | | — | | 3,389 | |||||
| Net loss | | — | | — | | — | | (85,474) | | — | | (85,474) | |||||
| Other comprehensive loss | | — | | — | | — | | — | | (1,314) | | (1,314) | |||||
| Balance at December 31, 2022 | | 53,797,341 | | $53 | | $726,630 | | $(566,232) | | $(1,672) | | $158,779 | |||||
| Net proceeds from sales of common stock under open market sales agreement | | 386,881 | | | — | | | 1,117 | | | — | | | — | | | 1,117 |
| Stock-based compensation expense | | — | | | — | | | 12,710 | | | — | | | — | | | 12,710 |
| Shares issued upon exercise of stock options | | 93,218 | | | 1 | | | 559 | | | — | | | — | | | 560 |
| Shares issued upon vesting of restricted stock units | | 203,264 | | | — | | | 1,020 | | | — | | | — | | | 1,020 |
| Net loss | | — | | | — | | | — | | | (118,513) | | | — | | | (118,513) |
| Other comprehensive income | | — | | | — | | | — | | | — | | | 1,412 | | | 1,412 |
| Balance at December 31, 2023 | | 54,480,704 | | $54 | | $742,036 | | $(684,745) | | $(260) | | $57,085 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.